Peter Olagunju - 01 Dec 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC.

Role: Chief Technical Officer
Signature: Margaret Siegel as Attorney-In-Fact
Issuer symbol: N/A
Transactions as of: 01 Dec 2022
Net transactions value: -$1,766
Form type: 4
Filing time: 05 Dec 2022, 18:50:38 UTC
Previous filing: 18 Nov 2022
Next filing: 07 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCRR	Common Stock	Options Exercise		+33,409	+1524%		35,601	01 Dec 2022	Direct	F1, F2
transaction	TCRR	Common Stock	Sale	$1,766	-1,273	-3.6%	$1.39	34,328	02 Dec 2022	Direct	F3
holding	TCRR	Common Stock						2,192	01 Dec 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TCRR	Restricted Stock Unit	Options Exercise	$0	+33,409	+117%	$0.000000	62,047	01 Dec 2022	Common Stock	33,409		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022 pursuant to the issuer's offer to exchange eligible options for new restricted stock units program.
F2	Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
F3	The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
F4	35% of these restricted stock units vested on December 1, 2022, 25% will vest on each of December 1, 2023 and December 1, 2024, and the remaining 15% will vest on December 1, 2025.